Title: Nordic Nanovector – Status of bookbuilding and increase in size of the offering
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL
Nordic Nanovector AS ("Nordic Nanovector" or the "Company") updates the market on the status of the bookbuilding for the Company's private placement, and references are made to the press releases from the Company dated 6 and 12 June 2014.
The offering has attracted strong investor interest since the launch and continues to see significant interest. On the basis of the strong investor demand, the Company has decided to increase the size of the offering to up to NOK 250 million and the indicative price is minimum NOK 25/share. The joint managers have registered orders such that the offering is also oversubscribed at minimum NOK 25/share and with the new offer size.
The bookbuilding period runs until 16:30 CET on 17 June 2014.
ABG Sundal Collier and DNB Markets are acting as managers in connection with the private placement.
Following completion of the private placement, the board of directors have decided to effect a subsequent repair issue towards existing shareholders at the same subscription price as in the offering. Further details will be announced in due course.
Jan A. Alfheim, CEO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 46 44 00 45
Fax: ( 47) 22 58 00 07
E-mail: jaa@nordicnanovector.no
Tone Kvåle, CFO
Phone: ( 47) 22 18 33 01
Cell: ( 47) 91 51 95 76
Fax: ( 47) 22 58 00 07
E-mail: tkv@nordicnanovector.no
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat Non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
